A Phase 3 interventional study of Herpes zoster vaccine (GSK 1437173A) and Placebo in Herpes Zoster, sponsored by GlaxoSmithKline. Completed at 86 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-06-06.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Herpes Zoster by GlaxoSmithKline — 3 open to participants now, 5 under way, 1 of them phase 3. Herpes Zoster · GlaxoSmithKline.
Among the 44 studies in Herpes Zoster by GlaxoSmithKline, this one is the 17th largest by enrollment of the 37 interventional ones that give a count, is one of 8 that started in 2013, is one of 25 in phase 3, and was the 15th registered.
299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.
Browse Herpes Zoster studies →3 of the 44 studies in Herpes Zoster by GlaxoSmithKline are open now, in 7 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Finland
Ages 76+ · Healthy volunteers
GlaxoSmithKline · Sites in Belgium, France, Italy and 3 more countries
Ages 1–17
GlaxoSmithKline
Ages 50+
By country, each count listing its studies:
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 25 · Phase 4 2
First in 2007; this study’s year is marked. 8 started in 2013.
This study's enrollment of 568 is above the median of 160 across 247 interventional studies indexed under Herpes Zoster.
Median enrollment 450 across the 37 interventional studies, 448 across the 7 observational. Of the 39 that completed or were terminated, 34 (87%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
1 of the studies in Herpes Zoster by GlaxoSmithKline that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05371080Phase 3GlaxoSmithKlineA Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults | 2027-08-23 |
Add it to your calendar (.ics) → With an account.
Among the 44 studies in Herpes Zoster by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and immunogenicity of GSK Biologicals' vaccine GSK1437173A in subjects aged 18 years and older with blood cancers. The study will evaluate safety-related events and antibody and cellular immune responses to the study vaccine, as compared to placebo.
Amendment to protocol posting:
Increase in sample size, update of country/region-specific information (Sections 5, 6 and 9).
Promotion of secondary to primary objective; related update of primary and secondary outcome measures (Sections 4 and 7).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female subjects of non- may be enrolled in the study.
Female subjects of childbearing potential may be enrolled inthe study, if the subject:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive the candidate HZ vaccine (GSK 1437173A).
Biological: Herpes zoster vaccine (GSK 1437173A)
Subjects will receive the placebo vaccine.
Drug: Placebo
2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm. Dose 1 administered at Day 0. Dose 2 administered 1-2 months post Dose 1.
2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm. Dose 1 administered at Day 0. Dose 2 administered 1-2 months post Dose 1.
Vaccine Response Rates (VRR) for Anti-glycoprotein E (Anti-gE) Antibody Concentrations
Vaccine response rate refers to the percentage of subjects with a vaccine response, as determined by Enzyme-Linked Immunosorbent Assay (ELISA). Vaccine response was defined as: For initially seronegative subjects, antibody concentration at Month 2 greater than or equal to (≥) 4 fold the cut-off for Anti-gE \[4x97 milli-international units per milliliter (mIU/mL)\]. For initially seropositive subjects, antibody concentration at Month 2 ≥ 4 fold the pre-vaccination antibody concentration. This analysis was performed on subjects with haematologic malignancies excluding subjects with Non-Hodgkin B-cell Lymphoma and Chronic Lymphocytic Leukaemia.
Time frame: At Month 2
Adjusted Geometric Mean Concentration of Anti-gE Antibodies
The Adjusted geometric mean concentration was measured in all subjects excluding those with Non-Hodgkin B-cell Lymphoma and Chronic Lymphocytic Leukaemia.
Time frame: At Month 2
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Number of Days With Solicited Local Symptoms
Solicited local symptoms: pain, redness, swelling and their number of days were recorded after each vaccination dose.
Time frame: Within the 7-day (Days 0-6) post-vaccination period
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (included nausea, vomiting, diarrhoea and/or abdominal pain), headache, myalgia, shivering and fever \[defined as oral, axillary or tympanic route measured temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Number of Days With Solicited General Symptoms
Solicited general symptoms: fatigue, gastrointestinal symptoms, headache, myalgia, shivering, temperature and their number of days were recorded after each vaccination dose.
Time frame: Withing the 7-day (Day 0-6) post-vaccination period
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study. It also included any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
Time frame: Within the 30-day (Days 0-29) post-vaccination period
Number of Subjects With Serious Adverse Events (SAEs)
A Serious adverse event (SAE) is any untoward medical occurrence that result in death, is life threatening, requires hospitalisation or prolongation of existing hospitalisation, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study subject. Related = SAEs assessed by the investigator as causally related to the study vaccination
Time frame: From first vaccination up to 30 days post last vaccination
Number of Subjects Reporting Any and Related Potential Immune-mediated Diseases (pIMDs)
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Related = pIMds assessed by the investigator as causally related to the study vaccination
Time frame: From first vaccination up to 30 days post last vaccination
Vaccine Response Rate (VRR) for Anti-gE Antibody Concentrations
Vaccine response rate refers to the percentage of subjects with a vaccine response, as determined by ELISA. Vaccine response was defined as: For initially seronegative subjects, antibody concentration at Month 2 ≥ 4 fold the cut-off for Anti-gE (4x97 mIU/mL). For initially seropositive subjects, antibody concentration at Month 2 ≥ 4 fold the pre -vaccination antibody concentration. This analysis was performed on subjects with haematologic malignancies, excluding subjects with Non-Hodgkin B-cell Lymphoma.
Time frame: At Month 2
Anti-gE Antibody Concentrations
Antibody concentrations were determined by ELISA, presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL).This parameter was assessed in subjects with haematologic malignancies, excluding subjects with Non-Hodgkin B-cell Lymphoma.
Time frame: At Month 2
Time to Occurrence of Any Confirmed HZ Case
Time to occurrence of any confirmed HZ case is expressed in terms of incidence rate of subjects with at least one event. Hence, person-year rate = number of episodes (n)/ sum of follow-up period (censored at the first occurrence of an event) expressed in years (T\[year)\]). Follow-up period starts Day 1 of vaccination. Any clinically suspected case of HZ (defined as (1) a new rash characteristic of HZ (e.g., unilateral, dermatomal and accompanied by pain broadly defined to include allodynia, pruritus or other sensations), or a vesicular rash suggestive of Varicella Zoster Virus (VZV) infection regardless of the distribution, and no alternative diagnosis; or (2) a clinical presentation (symptoms and/or signs) and specific laboratory findings suggestive of VZV infection in the absence of characteristic HZ or VZV rash.) The endpoint is confirmed in two ways: (1) By Polymerase Chain Reaction (PCR) or (2) By the HZ Ascertainment Committee. The PCR is used as primary classification method.
Time frame: From Month 0 until study end (Month 13)
Anti-gE Antibody Concentrations
Antibody concentrations were determined by ELISA, presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). This parameter was assessed in all vaccinated subjects.
Time frame: At Months 0, 1, 2 and 13
Vaccine Response Rate (VRR) for Anti-gE Antibody Concentrations
Vaccine response rate refers to the percentage of subjects with a vaccine response, as determined by ELISA. Vaccine response was defined as: For initially seronegative subjects, antibody concentration at Month 2 ≥ 4 fold the cut-off for anti-gE (4x97 mIU/mL). For initially seropositive subjects, antibody concentration at Month 2 ≥ 4 fold the pre -vaccination antibody concentration. Vaccine response was measured in all subjects.
Time frame: At Months 1, 2 and 13
Frequency of gE -Specific Cluster of Differentiation 4 (CD4) [2+] T-cells Expressing at Least 2 Activation Markers
Among markers expressed were interferon-gamma (IFN-γ), interleukin-2 (IL-2), tumour necrosis factor-alpha (TNF-α) and cluster of differentiation 40 ligand (CD40L), as determined by in vitro intracellular cytokine staining (ICS).
Time frame: At Months 0, 1, 2 and 13
Vaccine Response Rates (VRR) for gE-specific CD4 [2+] T-cells, Expressing at Least 2 Activation Markers
Among markers expressed were IFN-γ, IL-2, TNF-α and CD40L, as determined by in vitro ICS. Vaccine response was defined as: For initially subjects with pre-vaccination T-cell frequencies below the threshold, at least a 2-fold increase as compared to the threshold (2x\<320\> Events/106 CD4+ T cells). For initially subjects with pre-vaccination T-cell frequencies above the threshold, at least a 2-fold increase as compared to pre-vaccination T-cell frequencies.
Time frame: At Months 1, 2 and 13
Number of Subjects With Serious Adverse Events (SAEs)
A Serious adverse event (SAE) is any untoward medical occurrence that result in death, is life threatening, requires hospitalisation or prolongation of existing hospitalisation, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study subject. Related = SAEs assessed by the investigator as causally related to the study vaccination
Time frame: From first vaccination at Month 0 up to study end at Month 13
Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs)
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology
Time frame: From first vaccination at Month 0 up to study end at Month 13
Geometric Mean Concentrations (GMCs) of Anti-gE Antibodies
GMCs of anti-gE antibodies were tabulated per study group and HZ confirmed/non-confirmed status and expressed in milli-international units per milliliter (mIU/mL).
Time frame: At Months 0 and 2
Mean Geometric Increase (MGI) of Anti-gE Antibody ELISA Concentrations
MGI was tabulated per study group and HZ confirmed/non-confirmed status. MGI was defined as the Geometric mean of the within subject ratios of the post-vaccination reciprocal anti-gE concentration to the Month 0 reciprocal anti-gE concentration.
Time frame: At Month 2
| Milestone | GSK1437173A Group | Placebo Group |
|---|---|---|
| Started | 283 | 279 |
| Completed | 266 | 259 |
| Not completed | 17 | 20 |
| Withdrew: Adverse event | 8 | 8 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Withdrawal by subject | 7 | 10 |
| Withdrew: Suspected herpes zoster episode | 0 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Subject unavailable | 0 | 1 |
| Milestone | GSK1437173A Group | Placebo Group |
|---|---|---|
| Started | 283 | 279 |
| Completed | 236 | 216 |
| Not completed | 47 | 63 |
| Withdrew: Adverse event | 29 | 39 |
| Withdrew: Protocol violation | 2 | 0 |
| Withdrew: Withdrawal by subject | 9 | 14 |
| Withdrew: Migrated/moved from study area | 0 | 3 |
| Withdrew: Lost to follow-up | 6 | 4 |
| Withdrew: Suspected herpes zoster episode | 0 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Subject unavailable | 0 | 2 |
Vaccine response rate refers to the percentage of subjects with a vaccine response, as determined by Enzyme-Linked Immunosorbent Assay (ELISA). Vaccine response was defined as: For initially seronegative subjects, antibody concentration at Month 2 greater than or equal to (≥) 4 fold the cut-off for Anti-gE \[4x97 milli-international units per milliliter (mIU/mL)\]. For initially seropositive subjects, antibody concentration at Month 2 ≥ 4 fold the pre-vaccination antibody concentration. This analysis was performed on subjects with haematologic malignancies excluding subjects with Non-Hodgkin B-cell Lymphoma and Chronic Lymphocytic Leukaemia.
| Percentage | GSK1437173A Group | Placebo Group |
|---|---|---|
| Vaccine Response Rates (VRR) for Anti-glycoprotein E (Anti-gE) Antibody Concentrations | 80.4 (73.1 to 86.5) | 0.8 (0.0 to 4.2) |
The Adjusted geometric mean concentration was measured in all subjects excluding those with Non-Hodgkin B-cell Lymphoma and Chronic Lymphocytic Leukaemia.
| mIU/mL | GSK1437173A Group | Placebo Group |
|---|---|---|
| Adjusted Geometric Mean Concentration of Anti-gE Antibodies | 22132.9 (16642.8 to 32153.9) | 777.6 (702.8 to 860.3) |
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Any Pain, Dose 1 | 199 | 26 |
| Grade 3 Pain, Dose 1 | 16 | 0 |
| Any Redness, Dose 1 | 80 | 1 |
| Grade 3 Redness, Dose 1 | 2 | 0 |
| Any Swelling, Dose 1 | 47 | 2 |
| Grade 3 Swelling, Dose 1 | 1 | 0 |
| Any Pain, Dose 2 | 172 | 31 |
| Grade 3 Pain, Dose 2 | 20 | 0 |
| Any Redness, Dose 2 | 82 | 5 |
| Grade 3 Redness, Dose 2 | 10 | 0 |
| Any Swelling, Dose 2 | 42 | 1 |
| Grade 3 Swelling, Dose 2 | 5 | 0 |
| Any Pain, Across doses | 221 | 45 |
| Grade 3 Pain, Across doses | 29 | 0 |
| Any Redness, Across doses | 115 | 5 |
| Grade 3 Redness, Across doses | 12 | 0 |
| Any Swelling, Across doses | 63 | 2 |
| Grade 3 Swelling, Across doses | 5 | 0 |
Solicited local symptoms: pain, redness, swelling and their number of days were recorded after each vaccination dose.
| Days | GSK1437173A Group | Placebo Group |
|---|---|---|
| Pain, Dose 1 | 3.0 (2.0 to 4.0) | 1.0 (1.0 to 2.0) |
| Pain, Dose 2 | 3.0 (2.0 to 4.0) | 2.0 (1.0 to 3.0) |
| Redness, Dose 1 | 3.0 (2.0 to 5.0) | 1.0 (1.0 to 1.0) |
| Redness, Dose 2 | 3.0 (2.0 to 5.0) | 4.0 (2.0 to 6.0) |
| Swelling, Dose 1 | 3.0 (2.0 to 4.0) | 1.5 (1.0 to 2.0) |
| Swelling, Dose 2 | 3.0 (2.0 to 4.0) | 4.0 (4.0 to 4.0) |
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (included nausea, vomiting, diarrhoea and/or abdominal pain), headache, myalgia, shivering and fever \[defined as oral, axillary or tympanic route measured temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Any fatigue, Dose 1 | 122 | 73 |
| Grade 3 fatigue, Dose 1 | 11 | 8 |
| Related fatigue, Dose 1 | 37 | 11 |
| Any gastrointestinal, Dose 1 | 48 | 24 |
| Grade 3 gastrointestinal, Dose 1 | 5 | 2 |
| Related gastrointestinal, Dose 1 | 13 | 1 |
| Any headache, Dose 1 | 70 | 40 |
| Grade 3 headache, Dose 1 | 3 | 3 |
| Related headache, Dose 1 | 29 | 10 |
| Any myalgia, Dose 1 | 80 | 35 |
| Grade 3 myalgia, Dose 1 | 11 | 0 |
| Related myalgia, Dose 1 | 33 | 10 |
| Any shivering, Dose 1 | 39 | 16 |
| Grade 3 shivering, Dose 1 | 2 | 0 |
| Related shivering, Dose 1 | 14 | 2 |
| Any temperature, Dose 1 | 33 | 15 |
| Grade 3 temperature, Dose 1 | 0 | 1 |
| Related temperature, Dose 1 | 18 | 3 |
| Any fatigue, Dose 2 | 126 | 67 |
| Grade 3 fatigue, Dose 2 | 16 | 6 |
| Related fatigue, Dose 2 | 49 | 13 |
| Any gastrointestinal, Dose 2 | 53 | 16 |
| Grade 3 gastrointestinal, Dose 2 | 5 | 2 |
| Related gastrointestinal, Dose 2 | 20 | 4 |
| Any headache, Dose 2 | 90 | 42 |
| Grade 3 headache, Dose 2 | 10 | 3 |
| Related headache, Dose 2 | 42 | 9 |
| Any myalgia, Dose 2 | 93 | 25 |
| Grade 3 myalgia, Dose 2 | 14 | 5 |
| Related myalgia, Dose 2 | 50 | 7 |
| Any shivering, Dose 2 | 48 | 7 |
| Grade 3 shivering, Dose 2 | 9 | 0 |
| Related shivering, Dose 2 | 27 | 1 |
| Any temperature, Dose 2 | 51 | 11 |
| Grade 3 teamperature, Dose 2 | 3 | 0 |
| Related temperature, Dose 2 | 28 | 3 |
| Any fatigue, Across doses | 162 | 102 |
| Grade 3 fatigue, Across doses | 23 | 10 |
| Related fatigue, Across doses | 63 | 22 |
| Any gastrointestinal, Across doses | 76 | 29 |
| Grade 3 gastrointestinal, Across doses | 9 | 3 |
| Related gastrointestinal, Across doses | 28 | 5 |
| Any headache, Across doses | 115 | 64 |
| Grade 3 headache, Across doses | 12 | 6 |
| Related headache, Across doses | 52 | 16 |
| Any myalgia, Across doses | 122 | 48 |
| Grade 3 myalgia, Across doses | 22 | 5 |
| Related myalgia, Across doses | 63 | 15 |
| Any shivering, Across doses | 69 | 18 |
| Grade 3 shivering, Across doses | 11 | 0 |
| Related shivering, Across doses | 36 | 2 |
| Any temperature, Across doses | 68 | 21 |
| Grade 3 temperature, Across doses | 3 | 1 |
| Related teamperature, Across doses | 36 | 4 |
Solicited general symptoms: fatigue, gastrointestinal symptoms, headache, myalgia, shivering, temperature and their number of days were recorded after each vaccination dose.
| Days | GSK1437173A Group | Placebo Group |
|---|---|---|
| Fatigue, Dose 1 | 3.0 (1.0 to 6.0) | 3.0 (2.0 to 7.0) |
| Fatigue, Dose 2 | 3.0 (2.0 to 5.0) | 3.0 (1.0 to 7.0) |
| Gastrointestinal symptoms, Dose 1 | 2.5 (1.0 to 5.0) | 3.5 (1.5 to 6.0) |
| Gastrointestinal symptoms, Dose 2 | 2.0 (1.0 to 3.0) | 6.0 (2.5 to 7.0) |
| Headache, Dose 1 | 2.0 (1.0 to 3.0) | 1.5 (1.0 to 3.0) |
| Headache, Dose 2 | 2.0 (1.0 to 3.0) | 1.0 (1.0 to 3.0) |
| Myalgia, Dose 1 | 3.5 (2.0 to 5.5) | 3.0 (1.0 to 4.0) |
| Myalgia, Dose 2 | 2.0 (2.0 to 4.0) | 3.0 (1.0 to 7.0) |
| Shivering, Dose 1 | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 3.5) |
| Shivering, Dose 2 | 1.0 (1.0 to 2.0) | 4.0 (2.0 to 4.0) |
| Temperature, Dose 1 | 1.0 (1.0 to 2.0) | 2.0 (1.0 to 3.0) |
| Temperature, Dose 2 | 1.0 (1.0 to 2.0) | 2.0 (1.0 to 4.0) |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study. It also included any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Any AEs | 134 | 128 |
| Grade 3 AEs | 25 | 28 |
| Related AEs | 19 | 5 |
A Serious adverse event (SAE) is any untoward medical occurrence that result in death, is life threatening, requires hospitalisation or prolongation of existing hospitalisation, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study subject. Related = SAEs assessed by the investigator as causally related to the study vaccination
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| At least one SAE | 17 | 29 |
| Related SAEs | 0 | 0 |
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Related = pIMds assessed by the investigator as causally related to the study vaccination
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Any pIMDs | 1 | 0 |
| Related pIMDs | 0 | 0 |
Vaccine response rate refers to the percentage of subjects with a vaccine response, as determined by ELISA. Vaccine response was defined as: For initially seronegative subjects, antibody concentration at Month 2 ≥ 4 fold the cut-off for Anti-gE (4x97 mIU/mL). For initially seropositive subjects, antibody concentration at Month 2 ≥ 4 fold the pre -vaccination antibody concentration. This analysis was performed on subjects with haematologic malignancies, excluding subjects with Non-Hodgkin B-cell Lymphoma.
| Percentage | GSK1437173A Group | Placebo Group |
|---|---|---|
| Vaccine Response Rate (VRR) for Anti-gE Antibody Concentrations | 69.0 (61.8 to 75.6) | 0.6 (0.0 to 3.3) |
Antibody concentrations were determined by ELISA, presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL).This parameter was assessed in subjects with haematologic malignancies, excluding subjects with Non-Hodgkin B-cell Lymphoma.
| mIU/mL | GSK1437173A Group | Placebo Group |
|---|---|---|
| Anti-gE Antibody Concentrations | 15795.5 (11603.3 to 21502.2) | 791.6 (648.9 to 965.5) |
Time to occurrence of any confirmed HZ case is expressed in terms of incidence rate of subjects with at least one event. Hence, person-year rate = number of episodes (n)/ sum of follow-up period (censored at the first occurrence of an event) expressed in years (T\[year)\]). Follow-up period starts Day 1 of vaccination. Any clinically suspected case of HZ (defined as (1) a new rash characteristic of HZ (e.g., unilateral, dermatomal and accompanied by pain broadly defined to include allodynia, pruritus or other sensations), or a vesicular rash suggestive of Varicella Zoster Virus (VZV) infection regardless of the distribution, and no alternative diagnosis; or (2) a clinical presentation (symptoms and/or signs) and specific laboratory findings suggestive of VZV infection in the absence of characteristic HZ or VZV rash.) The endpoint is confirmed in two ways: (1) By Polymerase Chain Reaction (PCR) or (2) By the HZ Ascertainment Committee. The PCR is used as primary classification method.
| Person-year rate | GSK1437173A Group | Placebo Group |
|---|---|---|
| Time to Occurrence of Any Confirmed HZ Case | 0.020 (0.009 to 0.045) | 0.071 (0.045 to 0.111) |
Antibody concentrations were determined by ELISA, presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). This parameter was assessed in all vaccinated subjects.
| mIU/mL | GSK1437173A Group | Placebo Group |
|---|---|---|
| Anti-gE, Month 0 | 964.0 (814.5 to 1140.8) | 883.7 (749.9 to 1041.4) |
| Anti-gE, Month 1 | 4216.5 (3328.6 to 5341.4) | 824.2 (699.4 to 971.3) |
| Anti-gE, Month 2 | 13445.6 (10158.9 to 17795.6) | 832.0 (701.1 to 987.3) |
| Anti-gE, Month 13 | 5202.7 (4074.8 to 6642.8) | 895.4 (734.5 to 1091.5) |
Vaccine response rate refers to the percentage of subjects with a vaccine response, as determined by ELISA. Vaccine response was defined as: For initially seronegative subjects, antibody concentration at Month 2 ≥ 4 fold the cut-off for anti-gE (4x97 mIU/mL). For initially seropositive subjects, antibody concentration at Month 2 ≥ 4 fold the pre -vaccination antibody concentration. Vaccine response was measured in all subjects.
| Percentage | GSK1437173A Group | Placebo Group |
|---|---|---|
| VRR, anti-gE, Month 1 | 44.2 (37.4 to 51.1) | 0.0 (0.0 to 1.9) |
| VRR, anti-gE, Month 2 | 65.4 (58.7 to 71.7) | 0.5 (0.0 to 2.8) |
| VRR, anti-gE, Month 13 | 52.1 (44.2 to 59.9) | 3.6 (1.2 to 8.1) |
Among markers expressed were interferon-gamma (IFN-γ), interleukin-2 (IL-2), tumour necrosis factor-alpha (TNF-α) and cluster of differentiation 40 ligand (CD40L), as determined by in vitro intracellular cytokine staining (ICS).
| CD4 [2+] T-cells/million T-cells | GSK1437173A Group | Placebo Group |
|---|---|---|
| CD4 [2+], Month 0 | 226.78 ± 659.84 | 147.30 ± 191.91 |
| CD4 [2+], Month 1 | 1261.67 ± 2318.36 | 196.74 ± 332.52 |
| CD4 [2+], Month 2 | 6083.98 ± 10467.57 | 318.20 ± 1000.90 |
| CD4 [2+], Month 13 | 3626.87 ± 7758.18 | 181.23 ± 387.90 |
Among markers expressed were IFN-γ, IL-2, TNF-α and CD40L, as determined by in vitro ICS. Vaccine response was defined as: For initially subjects with pre-vaccination T-cell frequencies below the threshold, at least a 2-fold increase as compared to the threshold (2x\<320\> Events/106 CD4+ T cells). For initially subjects with pre-vaccination T-cell frequencies above the threshold, at least a 2-fold increase as compared to pre-vaccination T-cell frequencies.
| Percentage | GSK1437173A Group | Placebo Group |
|---|---|---|
| CD4 [2+], Month 1 | 37.5 (24.0 to 52.6) | 2.1 (0.1 to 11.3) |
| CD4 [2+], Month 2 | 83.7 (69.3 to 93.2) | 6.8 (1.4 to 18.7) |
| CD4 [2+], Month 13 | 66.7 (48.2 to 82.0) | 6.5 (0.8 to 21.4) |
A Serious adverse event (SAE) is any untoward medical occurrence that result in death, is life threatening, requires hospitalisation or prolongation of existing hospitalisation, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study subject. Related = SAEs assessed by the investigator as causally related to the study vaccination
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| At least one SAE, up to Month 6 | 50 | 60 |
| Related SAEs, up to Month 6 | 0 | 1 |
| At least one SAE, up to Month 13 | 66 | 82 |
| Related SAEs, up to Month 13 | 1 | 1 |
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Up to Month 6 | 3 | 1 |
| Up to Month 13 | 3 | 2 |
GMCs of anti-gE antibodies were tabulated per study group and HZ confirmed/non-confirmed status and expressed in milli-international units per milliliter (mIU/mL).
| mIU/ml | GSK1437173A HZ Cases Sub-Group | GSK1437173A Non-HZ Cases Sub-Group | Placebo HZ Cases Sub-Group | Placebo Non-HZ Cases Sub-Group |
|---|---|---|---|---|
| PRE | 115.9 (0.0 to 7406196) | 973.6 (835.6 to 1134.4) | 984.5 (500.7 to 1935.7) | 866.3 (745.5 to 1006.6) |
| Month 2 | 184.0 (0.0 to 4187800000) | 12517.4 (9662.0 to 16216.6) | 960.5 (454.2 to 2031.1) | 802.9 (686.7 to 938.9) |
MGI was tabulated per study group and HZ confirmed/non-confirmed status. MGI was defined as the Geometric mean of the within subject ratios of the post-vaccination reciprocal anti-gE concentration to the Month 0 reciprocal anti-gE concentration.
| Ratio | GSK1437173A HZ Cases Sub-Group | GSK1437173A Non-HZ Cases Sub-Group | Placebo HZ Cases Sub-Group | Placebo Non-HZ Cases Sub-Group |
|---|---|---|---|---|
| Mean Geometric Increase (MGI) of Anti-gE Antibody ELISA Concentrations | 1.59 (0.00 to 565.45) | 13.07 (9.93 to 17.22) | 0.98 (0.80 to 1.19) | 0.94 (0.88 to 1.00) |
Collected over Solicited and unsolicited symptoms: within the 30-day (Days 0-29) post-vaccination period; SAEs: up to study end, at Month 13.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GSK1437173A Group | 29/283 (10.2%) | 66/283 (23.3%) | 252/283 (89%) |
| Placebo Group | 37/279 (13.3%) | 82/279 (29.4%) | 146/279 (52.3%) |
| Event | GSK1437173A Group | Placebo Group |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 14/283 | 11/279 |
| PneumoniaInfections and infestations | 11/283 | 11/279 |
| Acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/283 | 8/279 |
| SepsisInfections and infestations | 5/283 | 6/279 |
| Plasma cell myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/283 | 6/279 |
| Acute kidney injuryRenal and urinary disorders | 5/283 | 4/279 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/283 | 1/279 |
| PyrexiaGeneral disorders | 3/283 | 3/279 |
| Septic shockInfections and infestations | 3/283 | 3/279 |
| NeutropeniaBlood and lymphatic system disorders | 3/283 | 2/279 |
| Event | GSK1437173A Group | Placebo Group |
|---|---|---|
| PainGeneral disorders | 221/283 | 46/279 |
| FatigueGeneral disorders | 163/283 | 102/279 |
| MyalgiaMusculoskeletal and connective tissue disorders | 123/283 | 48/279 |
| ErythemaSkin and subcutaneous tissue disorders | 116/283 | 6/279 |
| HeadacheNervous system disorders | 115/283 | 65/279 |
| Gastrointestinal disorderGastrointestinal disorders | 76/283 | 29/279 |
| PyrexiaGeneral disorders | 74/283 | 24/279 |
| ChillsGeneral disorders | 69/283 | 19/279 |
| SwellingGeneral disorders | 63/283 | 2/279 |
| Age, Continuous(Years) | GSK1437173A Group | Placebo Group | Total |
|---|---|---|---|
| Mean | 56.8 ± 15.5 | 57.8 ± 14.9 | 57.3 ± 15.2 |
| Sex: Female, Male(Participants) | GSK1437173A Group | Placebo Group | Total |
|---|---|---|---|
| Female | 114 | 114 | 228 |
| Male | 169 | 165 | 334 |
| Race/Ethnicity, Customized(Participants) | GSK1437173A Group | Placebo Group | Total |
|---|---|---|---|
| Geographic ancestry — African Heritage / African American | 1 | 1 | 2 |
| Geographic ancestry — American Indian or Alaskan Native | 0 | 1 | 1 |
| Geographic ancestry — Asian - Central / South Asian Heritage | 5 | 6 | 11 |
| Geographic ancestry — Asian - East Asian Heritage | 57 | 60 | 117 |
| Geographic ancestry — Asian - South East Asian Heritage | 4 | 1 | 5 |
| Geographic ancestry — White - Arabic / North African Heritage | 0 | 1 | 1 |
| Geographic ancestry — White - Caucasian / European Heritage | 198 | 186 | 384 |
| Geographic ancestry — Other | 7 | 12 | 19 |
| Geographic ancestry — Missing | 11 | 11 | 22 |
The record gives a start of Mar 2013, a primary completion of Jan 2016 and a completion of Jan 2017. It does not say whether these dates are actual or estimated.
Results were first posted in May 2017, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Herpes Zoster Vaccine